Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Peking University First Hospital
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
39Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03200600CT.gov Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Delirium
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Flurbiprofen Axetil (this asset) | Peking University First Hospital | Approved | CCC · 54 |
| Propofol | RenJi Hospital | P4 | BB |
| Isoflurane | Duke University | P4 | BB |
| Amantadine | Methodist Rehabilitation Center | P4 | BB |
| Cyclopofol | RenJi Hospital | P4 | BB |
| .Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio- | Konkuk University Medical Center | P4 | BB |
| Pyridostigmine | Konkuk University Medical Center | P4 | BB |
| Suvorexant | Mayo Clinic | P4 | BB |
| Clonidine | Insel Gruppe AG, University Hospital Bern | P4 | BB |
+14 more in the Delirium cohort
Other indications for Flurbiprofen Axetil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Iatrogenic Disease | — | P4 | CCC · 54 |
| Non-Small Cell Lung Carcinoma | — | P4 | CCC · 49 |
| Atrial Fibrillation | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Flurbiprofen Axetil in Delirium. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/flurbiprofen-axetil-delirium
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →